Product Description
An orally administered adjunct treatment option for epilepsy patients who lack seizure control or who are unable to tolerate the side effects of their currently prescribed therapies. The primary objective of the Phase 2 study is to assess the efficacy of NPT 2042 compared with placebo as an adjunctive treatment for focal-onset epilepsy. (Sourced from: https://neuropro.io/providers/)
Mechanisms of Action: Unknown
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: N/A
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: NeuroPro Therapeutics, Inc.
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|